AAA
XENE icon

Affinity Asset Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Affinity Asset Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$97.4M Buy
1,675,000
+425,000
+34% +$19.6M 5.03% 3
2025
Q4 		$56M Sell
1,250,000
-150,000
-11% -$6.3M 3.19% 7
2025
Q3 		$56.2M Buy
1,400,000
+300,000
+27% +$10.6M 4.9% 4
2025
Q2 		$34.4M Sell
1,100,000
-228,175
-17% -$7.44M 4.7% 3
2025
Q1 		$44.6M Buy
1,328,175
+166,938
+14% +$6.34M 4.25% 3
2024
Q4 		$45.5M Buy
1,161,237
+17,216
+2% +$712K 6.1% 2
2024
Q3 		$45M Buy
1,144,021
+149,794
+15% +$6.04M 6.15% 1
2024
Q2 		$38.8M Buy
994,227
+156,840
+19% +$6.27M 4.47% 2
2024
Q1 		$36M Buy
837,387
+377,387
+82% +$17.4M 4.46% 4
2023
Q4 		$21.2M Buy
460,000
+159,562
+53% +$5.64M 3.87% 5
2023
Q3 		$10.3M Buy
300,438
+240,062
+398% +$8.98M 2.89% 12
2023
Q2 		$2.32M Sell
60,376
-29,624
-33% -$1.18M 0.81% 35
2023
Q1 		$3.22M Buy
90,000
+40,000
+80% +$1.48M 1.06% 29
2022
Q4 		$1.97M Buy
+50,000
New +$1.82M 0.77% 40
2022
Q2 		– Sell
-80,000
Closed -$2.45M – 70
2022
Q1 		$2.45M Sell
80,000
-70,500
-47% -$2.11M 0.39% 35
2021
Q4 		$4.7M Buy
150,500
+100,500
+201% +$3M 1.71% 26
2021
Q3 		$764K Buy
+50,000
New +$869K 0.19% 64

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Affinity Asset Advisors's XENE Position: Q1 2026 in Review

Affinity Asset Advisors increased its Xenon Pharmaceuticals (XENE) stake by 34% in Q1 2026, buying an estimated $19.6M and bringing the position to 1,675,000 shares worth $97.4M. The position accounts for 5.03% of the portfolio, ranked #3.

Affinity Asset Advisors first reported a position in XENE in Q3 2021 and has held it in 17 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Affinity Asset Advisors held 1,675,000 shares of Xenon Pharmaceuticals worth $97.4M as of Q1 2026.
  • Affinity Asset Advisors bought 425,000 Xenon Pharmaceuticals shares in Q1 2026, an estimated $19.6M.
  • Xenon Pharmaceuticals made up 5.03% of Affinity Asset Advisors's portfolio in Q1 2026, its #3 holding.
  • Affinity Asset Advisors first reported a position in Xenon Pharmaceuticals in Q3 2021 and has held it in 17 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.